Investments in biotech: new horizons and growth opportunities

The international forum “BIOPROM: Industry and Technologies for People” took place in Gelendzhik, bringing together the key players of the biotechnology sector, as well as representatives from business, government, and the scientific community to discuss the latest issues in market development.

On October 7, KAMA FLOW partner Evgeny Borisov spoke as a panelist in the session “From Science to IPO: Where to Find Money for the Bioeconomy?”. During the discussion, experts explored the most relevant and in-demand tools for financing biotech projects at various stages — from grants and crowdfunding to the issuance of digital financial assets and going public. The panel also examined in detail the current landscape for attracting “long money” and addressed the challenges facing the integration of new developments into large-scale business processes.

The panel paid special attention to the prospects for IPOs among Russian biotech companies, and how successful public offerings can influence the sector’s investment climate. According to Evgeny Borisov, 2024 has become a milestone year for Russian biotech: “The successful IPOs of ‘Promomed’ and ‘Ozon Pharmaceuticals’ are an important signal for the market: Russian biotech is becoming a mature investment segment with growing potential. The key task now is the balanced allocation of budgetary flows and the development of mechanisms to attract private capital. The scientific foundation is enormous, and today is one of the best times to build long-term partnerships in the industry.”